NDAOPHTHALMICFOR SUSPENSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYCETIN HYDROCORTISONE is a fixed-dose ophthalmic suspension combining chloramphenicol (a broad-spectrum antibiotic) and hydrocortisone acetate (a corticosteroid) approved in 1953. It is indicated for bacterial eye infections with inflammatory components. The combination provides antimicrobial activity while reducing ocular inflammation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating a defensive positioning phase with likely transition from growth to sustainability teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHLOROMYCETIN HYDROCORTISONE offers limited growth trajectory but strong opportunity to develop defensive commercial strategy, competitive positioning, and lifecycle management skills. This assignment is best suited to mid-career professionals seeking expertise in mature product optimization and generic transition planning.
Brand ManagerProduct Manager
Worked on CHLOROMYCETIN HYDROCORTISONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.